Related Experiment Video
Updated: Mar 30, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.8K
Pharmacotherapeutic options for hepatitis B.
1a Liver Research Unit, Chang Gung Memorial Hospital , Chang Gung University College of Medicine , Taipei , Taiwan.
Expert Opinion on Pharmacotherapy
|November 13, 2015
Summary
Choosing the right Hepatitis B treatment is crucial for managing chronic infection. Nucleos(t)ide analogs (Nuc) offer long-term efficacy, while pegylated interferon-α (PEG IFN) suits specific patient groups.
Area of Science:
- Hepatology and Virology
- Infectious Diseases
- Pharmacotherapy
Background:
- Hepatitis B virus (HBV) drives chronic hepatitis B progression.
- Timely treatment is essential for patients with active HBV replication or significant liver disease.
- Current first-line treatments include pegylated interferon-α (PEG IFN), entecavir (ETV), and tenofovir disoproxil fumarate (TDF).
Purpose of the Study:
- To review current treatment strategies for chronic Hepatitis B.
- To compare the efficacy and safety of different therapeutic options.
- To provide guidance on selecting appropriate treatments based on patient profiles and outcomes.
Main Methods:
- Review of finite course PEG IFN therapy and its outcomes.
- Analysis of nucleos(t)ide analogs (Nuc) therapy, including safety, response, and long-term efficacy.
- Discussion of optimal Nuc duration and the development of stopping rules.
Main Results:
- Finite course PEG IFN therapy shows modest response rates but can reduce cirrhosis and hepatocellular carcinoma risk.
- Nuc therapy demonstrates an excellent safety profile with cumulative or maintained response and long-term efficacy in reducing fibrosis and preventing cirrhosis.
- The optimal duration for Nuc therapy remains undetermined, necessitating a defined stopping rule and monitoring plan.
Conclusions:
- Treatment selection for chronic Hepatitis B should prioritize patient outcomes.
- Nuc therapy is the preferred choice for patients with hepatic decompensation, pregnant women, and those undergoing specific medical treatments.
- PEG IFN-based therapy is recommended for patients with compensated liver disease, especially young patients and women of childbearing potential.
Related Concept Videos
01:25Hepatitis
37
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
37
01:30Inhibitors of Viral Protein Synthesis
24
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
257
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
296
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
296
01:17Hepatic Drug Excretion: Enterohepatic Cycling
3.3K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.3K